Novartis & Samsung Forge Five-Year๐ฌ Big news in biopharmaceuticals! Samsung Biologics is expanding its collaboration with Novartis to enhance their biologics manufacturing capabilities. The initial $81 million partnership has now grown into a five-year agreement worth nearly $391 million, marking a remarkable $309 million expansion. ๐
Over the past two years, the Ohio-based gene therapy manufacturer Forge Biologics has managed to get a large amount of capital to scale up its AAV production capabilities. And as the field continues to grow, the company looks to grow along with it.
Novartis & Samsung Forge Five-Year With a letter of intent signed, Novartis aims to secure the necessary manufacturing capacity for biologics drug substances. Samsung Biologics’ cutting-edge facility in Korea will serve as an additional supply hub for Europe and other markets with a rising demand for Novartis biologics. ๐ญ๐
Starting from 2024 until 2028, the focus of this five-year manufacturing and supply agreement will be on drug substance production. Samsung’s Korea-based facilities will play a crucial role in meeting the growing demand for Novartis biologics, providing additional supply capabilities to various markets. ๐ฑโจ
In November 2020, Samsung embarked on the construction of the world’s largest biopharmaceutical manufacturing facility in Incheon. Spanning approximately 2.5 million square feet, this remarkable $2 billion “superplant” began partial operations last year, contributing 240,000 liters of capacity. Consequently, Samsung’s overall manufacturing capacity now totals 604,000 liters. ๐ญ๐ก
